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Abstract 
The first hum<m Papillam;; virus (HPV) vaccine ""'"" 
approved in the United Statetl in 2006 with the potentia] to 
reduce cervical cancer and genital ·,>:3rts. Since then, its 
effic:acy in preventing HPV-rdated cancers in both m,;}es 
and female~ has been prom;sing. Despite CDC 
recommcndmiuns, opponents of the vaccine a5sert that 
V<:Jccinatir.g pre .. <;dolesc:ents and adolescents wrU incre<,se 
their sexual activity, a~ well as overtly c:ondo.ne risky sexui:ll 
behavior. We analyzed clinic data cf 499 adoh:::;ct:ntt: vvith a 
mean age of 16 years w c:xplorc v;hcther vc.cc:u;;Jtion kd to 
change in sexual behavior after one year. Our results 
showed no statis-tically significant difference i1~ either 
initiation of sexual !lctivity or d1ange in sex.u8l behavior 
when compared to peers, therefo;·e rd~;ling the asscrti<Jn 
that this rncthml of preventative h(~altbcarc pronwk.s 
promiscuity, Thus, we conclude that teenage sexual 
behavior is linked more clnsely to ethics, morality, and 
olher socio-cultural phenomena rather than H!'V vaccine 
itself. 
Keywords: Humll.n papilloma virus, vaccmation, 
adolescents, sexual bcha·vior. 
Introduction 
Tne lmman papillornavirns (HPV) is the mo~t 
comilJOri. sexua11y :.nmsrrdticd infection in the United 
States (1). 11m virus specifically target:;: the stratified 
epithelium of ~kin and mucous membranes. The 
infection can result in a spectrm:n of c.nnditions 
irwh1ding skin and anogcnital w;;rts, varii1us 
z_rwgenitaJ malignancies, and in wme cases -..s,ith 
nongcnita1 manik~tations. \'\/hi!e there are more than 
mie hundred subtypes of thu vints, the most common 
incluJe the lo'V'i risk subtypes, 6 and 
higher risk subtypes, 16 and 18. Jt is 
these fm;r subtypes done xesnlt in more U1a.J.1 
the cases of genital 'Narts, and about 70% 
of cervical cancer (2A) . 
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In 2006, the; first vaccine against HPV wa~:; 
approve<,l by the Food and Drug i\dministration. 
(FDA) for Dse in females aged 9 to 26 years old in a 
t4rava!cnt form targeting s1.1bcypcs 6, ll , 16 ai!.d 18 
(5). A bivalent vers:ion targeting types 16 and l R. wa.s 
later approved. in 2009 for prevention of (:t:rvical 
cam:e1· and other precancerous lesions, a.lso in fenu~.les 
(6). As lll<:sc vaccines were made availabl~:, tbe 
CDC's advisory committee on immunization practices 
(ACIP) concomitantly tecommended routine 
vaccination of .females ll-12 years old, or catch up 
vaccination i}; females aged 13-26 irrespective of 
previous sexual activity, a:-> well as in rn:ale aged 9-26 
(7 ,8); ultimately sparking a great debate across tP,e 
world. Given that the last time the vaccine--c<mcer link 
was realized in the 1980s '.:'lith the hepatitis B vat:cine 
and hepatoccHular cancer, lho HPV vaccine was 
viewed. with great promise. 
The efficacy of the vaccine itself ill 1m:vcntion of 
an array of cancers, including cervical, penile, 'Ylllva.r, 
vaginal, and anal can~:~;r, and pr~cancerous lesions (9-
11) woul.d at first glance s<:etn to outweigh any 
possible disadvantages. Early shldies looki11g ut tbe 
acceptabil~ty of the vaccine dcmi)nstratcd that nwst 
parents were in favor of vaccinating their daughters 
after certain criteria were achieved -including: whether 
the parent Hnderstood its effectiveness, whether the 
vaccin~ was recommended by a physician, and 
whether HPV infection was probable. Initial 
roadblocks cited included co.st~ and concerns that 
vaccination. promoted earlier sexual activity in young 
girls (]2). Looking at the .last five years, very little has 
changed in either of these obstacles. The price of 
vacoination has remained high for those wi!h no 
insurance Rnd OVL'r .18 years of age, totaling about 
$360 for the series of three vaccinations. while the 
cost ot oth~r childhood. vaccinations that prot('Ct 
against multiple diseases arc all less than S50. 
Likev.'ise, parents opposing vaccination remain 
vigilant that early vaccination wit! botb increase their 
child's sexual activity, allCl condone risky sexual 
behavior (13) . Since CDC rewmn:It~ndations for this 
particuiar vaccine arc fbr aJ.i older age group than 
oth<~r childhood vaccinations, parents WO!TY aho\lt <'.:UY 
PQ!'Sible questions their children rnay hav(',. 
Accurately and responsibly fielding these questions is 
~~{}ltle.thing plli-ents mo;:;t likely fear because of ideas it 
l11a)i·ignite in young impressionable mincb (14). 
There were many preconceptiom: about the H.PV 
vaccine even prim to its re-lease in 2006. One study ir1 
the late 1990s surveyed adolescent~ abo.ut hnw they 
believed teenage behavior would change after receipt 
of the vaccine. Surprisingly, 77% believed there 
\Vould he a substatttial increase ~n. risky sexual 
behavior {15). Tt is ca8y to ascerta·in thaf if adolescents 
have rhis misconception, that even greater numbers <>f 
parents would huve s1mi1ar notions f'.bout fhc vaccine. 
Years after landmark trials demonstrated the link 
between lli')V und cancer prevention, poor acceptance 
of be vaccine continut~d., akrti:ng t iS to problems 
reqwtmg fiuther atte.otlon. One study reported 
iindings from telephone surveys of parents of young 
girb m public schools aged ll ~ 18 years m 
economically disad"\o·a.ntaged area:; in Los Angeles, 
Californi.a b{~lween 2007-2008. More than two years 
after the vaccine · n'llcase, patents echoed earlier 
sentiments that the vaccine may be hanttful, costly, 
that their daughter wasn't old c;~ough to receive 
protection against an STI, and that the vaccine may 
lead to s'~xual activity (16). Additionally, 75% of 
surveyed parents wore f.1.mi1iar wilh the HPV vaccine. 
Of these, 75% were aware thr.t the1r daughter was 
eligible for the vaccine, and thal it: would be most 
beneficial prior ~o the uli.<:et of scxltal activity (16). 
Thio; study clearly l;{ernonstrates ~hat even though the 
public is educated about the ability and benefits of the 
vaccine, misconceptions about its side effects rqnain 
and need to be fi1rthcr adda~ssed. Future genemtiom1 
would he hdter served if socio-cultural ptcs.sttrt;s di<l 
not affe<.:t the prevention of cancer. 
b thh study, we analyzed clinical daia to 
investigate if the d aims of change in s~xyal behavior 
following HPV va:cc:ination were tn1e. 
l\tlethods 
All paticnL-s in our adolescent medicine clinic a:re 
screc11ed for all risk behaviors, including sexual 
activity at lhQir hsilial visit, then the risk behaviors are 
updated on each visit. Adok~cent female patient!'! 
attending our· 11dolescent clinic who w ere also 
receiving "the ITPV vaccine were chosen as 
partidpat:t{ fi)t our retrospective study. We analyzed 
the risk assessment fotms for quuJifyitlg females ut 
various time :points including prio~· to vaccination, 
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No s[gnijlcant change in sexur:l behavior ;, . . · 
upon completion of the vaccination senes, and one 
year later. This method provides c1inical data at 
diff.erent time points with reference to vaccination, 
allowing us to explore changes in sexuai behavior, A!.i 
addesccnt girls who have received the ·vaccine. were 
ind\,.lde<! :!n the study. Sexual activity data prior to the 
start of the vaccine series and at year aHer 
completioh <.if the series were analyzed. 
However, such a methcu is nut "';itht)~lt 
limitatiom~ a~s·umhlg that an outc.omes cnn be 
measured through these ohser.red variahlcs even if 
they arc partially affected by socio-e.r.viromnenta.l 
sourc0s. lu other ·.vords, it negkct.....:; the social and 
environmental influences on the dynamics .of teenage 
behavior. Regardless, it is sliti usct'hL to explore the 
assertion that vaccination \Vill lead to prom1scuijy 
since our ob.servat.'iuns on sexual behavior are in the 
san:1e indivi<'hJals. A simple comparison of sex\lal 
act1yity at. these separate points in time can g-~1ide 
future research. We present the results of itpplying a 
non·paramenjc approach to comparing sexua.l 
behavior in the same individual~ . 
Results 
There were 499 female ;;dole.scents who rec-eive-d the 
vaccine. At rhe ti.me of the first vaccination, the 
average age of the sample was 16.05 (sd'"'2,9.); 51.4% 
of the sample \Vas not sexually active i.e. claiming to 
have zero partners; the average age cf the sexually 
inactive group was 14.89 (sd'-"·2.98); l2% ofthe.totai 
wen; smok~:r~; 8% had abnormal PAP results; 6.8% 
had prior diagnosis of BPV. 'fhc variabl~ 'numbe:r of 
partners' was used to investigate ch<mge in sexual 
behavior foUovvii1g vaccination. 
Our firs t and most pressing question was whether 
there was a signitk<mt c:hange in the samp1e's sexual 
behavior folli)wing the vaccination, S~nc.e data 
collecte-d is from the same:: individuals at different 
points i.r: time, a matched (related samples) non~ 
parametric Vli1coxon signed nmk test was carried O\lt. 
At time 1, the start of the vaccination scrie:-:, 
51.4% of the sample claimed to be sexually inactive 
by not having a partner. At th.t~ end of one y~:ar, 51 .2% 
of the sample again claimed to be sexcmlly .inactlv(:. 
Obviously; a change of 0.2% ·is insignificant and does 
not wartant statisti<;al analysis. Additionally , one year 
after vaccinatio:i, 2.-8% Qfse:X't:ally 
act1v<t by having at least · one indtleJ;, 
2l5% of !{c;nJalJy active bce.ame i:\activ¢ ·. 
year; Agai.n, these arc relatively minor ·. • ....... . 
not warrant statistical analysi~. · .. ·.··· · ·. • · 
On the other end of the spcctnn:n . 
analysis of the sexuaLly active b>i"Otip. In. 
22. .6o/~, of claimed to hn·ve three or more 
•i•''l' 1 Aft~ ... one ye~.. rhis -i(·'(;f''· "iS~s •o 2'' r<tli 
... .... ~ ). ~ • . V..L ·a ... , ..... ... u " ·"",..." ~. "' .~ · ·. ~~-:t (a .. .. .. . 
Again, a change of 0.2% is very minQr and doe~ n\)l 
warrant statistical analysis. Of those claiming to have 
more than three paxtncn>, on" ycm· later 4.5% were 
sexually inactive, Conversely, of those wlw had 3 or 
more partners after one yca.r, 1.8% had none, 0.9% 
had one, and 0.9% had 1 partners at time 1. Again, 
these arc insignificant char;ges that do not require 
fiuiher analysis. 
IHscussion 
The premise of this study is to explore the assc1iinn 
that prevetllative health cate in the form of HPV 
vaccination m prc-ad.olcscenl.ii \V11l lead tn 
promiscuity. Two significant issues stem from this 
assertion. Pir~>t, we begin to question the nature of 
hea1thcare programs in the medical context, -and also 
in tcrmli of ito;; morality and socio-cultural phenomena. 
Second; we begin to question adolescents' ability to 
make decisions. Both of these i.ssu~~s are extre.m~ly 
complex, govemed ·by dynarnks of human behavior 
( 17,1 8) It is difficult to accurately quant;i.fy the effecti'. 
of wntiimou~ (.!Xposurc to stxLHtl material ~ssociated 
with the HPV vaccine in each distinctadolesc{!rit w.ha 
mayor may nol. have had any previous e·xposure .from 
the media, personal experienc:es} p:rrcnts, or even 
sexual education courses. How could \ Ve assess the 
inter<~ction between this conLinuou~ background 
exposure w]th health and social policies in ado.lcscent 
care? And would this so called 'negative' publjcity 
taint adoles-cents' decision making? In other \.VQrds, an 
assertion that obviously a.~soci.ates a healli:care 
program with sexual actiVity may in fact 
coll.nterprodu~.:tivc and detrimental; by doing so, 
increase exposure to sexu.al behavior, ign<lr~ 
adolescents' process of decision making; 
impminntly, make tlnsubstanliated a 
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\Ve quantify sexual activity of adolescents 
through the variable 'number of partners,' to explore 
adolescent ~'exual behavior. However, this clinical 
di1t3set is still limiting. The dataset used in this paper 
pnly prov-ides number of partners as reported by the 
participants at the time of each visit There is no 
objective way to verify this infom1atimL 
Nevertheless, <Ulalysi$ of our dataset stili yields the 
important conclusion that es:,;entially sexually non-
active adolescents remain sexually inactive after 
vaccinat!ons. Furthermore, there ts also some 
indication~ that change in behavior may be it~ both 
directions; a smaB proportion of those who had no 
partners at time one app(:ar to have at lea~<t o11c 
p;Hiner one year later •,vhich is. still less than would he 
expected by age change, ar:d, c<mversely, a small 
proportion of those wi!h at iea.st one pa:rtnc:r at !irne 
one <tppear not to have a partner a year later. If these 
results a<;curate1y ref1cct: adolescent behavior in the 
general population, we presume that vaccination anrl 
sexual behavior are unrcl<Jtcd. Moreover, WG 
speculate that at least in the short tenn, the real issue 
at hand is the ~:odal awl cultural facH1rs. 
Based on tbc n;:sult" of this study, vaccinating 
young girls with the HPV va~:cine does not alter their 
sexual behavior in a significant maurwr. Considering 
the health benefits of the vaccine, fear of a potential 
change in sexual behavior which does not seem to 
actually exist, should not get in the way of providing 
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